Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O15525
UPID:
MAFG_HUMAN
Alternative names:
V-maf musculoaponeurotic fibrosarcoma oncogene homolog G; hMAF
Alternative UPACC:
O15525
Background:
Transcription factor MafG, known as V-maf musculoaponeurotic fibrosarcoma oncogene homolog G or hMAF, plays a pivotal role in gene expression regulation. It acts as a transcriptional repressor when dimerizing among small Mafs but serves as an activator in conjunction with larger basic-zipper proteins like NFE2, NFE2L1, and NFE2L2. This duality facilitates specific DNA-binding site recruitment, influencing erythroid-specific transcription and globin gene expression.
Therapeutic significance:
Understanding the role of Transcription factor MafG could open doors to potential therapeutic strategies.